Eintrag weiter verarbeiten
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience
Gespeichert in:
| Zeitschriftentitel: | Acta Medica Marisiensis |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Acta Medica Marisiensis, 65, 2019, 1, S. 12-18 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Walter de Gruyter GmbH
|
| Schlagwörter: |
| author_facet |
Barcutean, Laura Iulia Maier, Smaranda Bajko, Zoltan Motataianu, Anca Romaniuc, Andreea Andone, Sebastian Razvan Balasa, Rodica Ioana Barcutean, Laura Iulia Maier, Smaranda Bajko, Zoltan Motataianu, Anca Romaniuc, Andreea Andone, Sebastian Razvan Balasa, Rodica Ioana |
|---|---|
| author |
Barcutean, Laura Iulia Maier, Smaranda Bajko, Zoltan Motataianu, Anca Romaniuc, Andreea Andone, Sebastian Razvan Balasa, Rodica Ioana |
| spellingShingle |
Barcutean, Laura Iulia Maier, Smaranda Bajko, Zoltan Motataianu, Anca Romaniuc, Andreea Andone, Sebastian Razvan Balasa, Rodica Ioana Acta Medica Marisiensis Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience General Pharmacology, Toxicology and Pharmaceutics General Dentistry |
| author_sort |
barcutean, laura iulia |
| spelling |
Barcutean, Laura Iulia Maier, Smaranda Bajko, Zoltan Motataianu, Anca Romaniuc, Andreea Andone, Sebastian Razvan Balasa, Rodica Ioana 2247-6113 Walter de Gruyter GmbH General Pharmacology, Toxicology and Pharmaceutics General Dentistry http://dx.doi.org/10.2478/amma-2019-0003 <jats:title>Abstract</jats:title> <jats:p> <jats:bold>Objective</jats:bold>: Interferon beta-1b (IFNβ-1b) was the first disease-modifying agent (DMT) used for the treatment of multiple sclerosis (MS). We aimed to evaluate the first patients with MS that started treatment in our clinic.</jats:p> <jats:p> <jats:bold>Methods</jats:bold>: An observational, retrospective study was performed on 78 patients that had continuous treatment with IFNβ-1b for more than 10 years. The collection of the demographical data and periodical clinical evaluation was performed on all patients. The disability was quantified using the Expanded Disability Status Scale (EDSS), creating two groups of patients, G1: EDSS < 4.0 and G2: EDSS ≥ 4.0. The hallmarks of the disability evolution were gathered by direct patient interview, such as the symptoms at onset and relapse frequency.</jats:p> <jats:p> <jats:bold>Results</jats:bold>: After more than 17 years of disease evolution, more than half (65.38%) of the patients present a mild disability score. The majority (54.90%) started treatment in the first three years after the onset, while the patients in G2 started treatment after more than 3 years from the onset. The initiation of IFNβ-1b lead to a significant reduction of the relapse rates. A reduced number of patients (<25%) transitioned from RRMS to SPMS.</jats:p> <jats:p> <jats:bold>Discussion</jats:bold>: Continuous evaluation of MS patients allows us to assess the possibility of prolonged treatment with IFNβ-1b and to differentiate the responders from non-responders. The clear reduction in relapse rates and disability progression, notably in patients that started treatment early ensure us into continuing administering this medication. Compared to historical cohorts, our lot had a slower disability evolution and a significant proportion hadn’t reach an important disability score.</jats:p> Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience Acta Medica Marisiensis |
| doi_str_mv |
10.2478/amma-2019-0003 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjQ3OC9hbW1hLTIwMTktMDAwMw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjQ3OC9hbW1hLTIwMTktMDAwMw |
| institution |
DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Walter de Gruyter GmbH, 2019 |
| imprint_str_mv |
Walter de Gruyter GmbH, 2019 |
| issn |
2247-6113 |
| issn_str_mv |
2247-6113 |
| language |
English |
| mega_collection |
Walter de Gruyter GmbH (CrossRef) |
| match_str |
barcutean2019interferonbeta1bforthetreatmentofmultiplesclerosismorethan10yearsofexperience |
| publishDateSort |
2019 |
| publisher |
Walter de Gruyter GmbH |
| recordtype |
ai |
| record_format |
ai |
| series |
Acta Medica Marisiensis |
| source_id |
49 |
| title |
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_unstemmed |
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_full |
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_fullStr |
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_full_unstemmed |
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_short |
Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_sort |
interferon beta-1b for the treatment of multiple sclerosis – more than 10 years of experience |
| topic |
General Pharmacology, Toxicology and Pharmaceutics General Dentistry |
| url |
http://dx.doi.org/10.2478/amma-2019-0003 |
| publishDate |
2019 |
| physical |
12-18 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>
<jats:bold>Objective</jats:bold>: Interferon beta-1b (IFNβ-1b) was the first disease-modifying agent (DMT) used for the treatment of multiple sclerosis (MS). We aimed to evaluate the first patients with MS that started treatment in our clinic.</jats:p>
<jats:p>
<jats:bold>Methods</jats:bold>: An observational, retrospective study was performed on 78 patients that had continuous treatment with IFNβ-1b for more than 10 years. The collection of the demographical data and periodical clinical evaluation was performed on all patients. The disability was quantified using the Expanded Disability Status Scale (EDSS), creating two groups of patients, G1: EDSS < 4.0 and G2: EDSS ≥ 4.0. The hallmarks of the disability evolution were gathered by direct patient interview, such as the symptoms at onset and relapse frequency.</jats:p>
<jats:p>
<jats:bold>Results</jats:bold>: After more than 17 years of disease evolution, more than half (65.38%) of the patients present a mild disability score. The majority (54.90%) started treatment in the first three years after the onset, while the patients in G2 started treatment after more than 3 years from the onset. The initiation of IFNβ-1b lead to a significant reduction of the relapse rates. A reduced number of patients (<25%) transitioned from RRMS to SPMS.</jats:p>
<jats:p>
<jats:bold>Discussion</jats:bold>: Continuous evaluation of MS patients allows us to assess the possibility of prolonged treatment with IFNβ-1b and to differentiate the responders from non-responders. The clear reduction in relapse rates and disability progression, notably in patients that started treatment early ensure us into continuing administering this medication. Compared to historical cohorts, our lot had a slower disability evolution and a significant proportion hadn’t reach an important disability score.</jats:p> |
| container_issue |
1 |
| container_start_page |
12 |
| container_title |
Acta Medica Marisiensis |
| container_volume |
65 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792330443981324293 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T13:25:10.514Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Interferon+Beta-1b+for+the+Treatment+of+Multiple+Sclerosis+%E2%80%93+More+than+10+Years+of+Experience&rft.date=2019-03-01&genre=article&issn=2247-6113&volume=65&issue=1&spage=12&epage=18&pages=12-18&jtitle=Acta+Medica+Marisiensis&atitle=Interferon+Beta-1b+for+the+Treatment+of+Multiple+Sclerosis+%E2%80%93+More+than+10+Years+of+Experience&aulast=Balasa&aufirst=Rodica+Ioana&rft_id=info%3Adoi%2F10.2478%2Famma-2019-0003&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792330443981324293 |
| author | Barcutean, Laura Iulia, Maier, Smaranda, Bajko, Zoltan, Motataianu, Anca, Romaniuc, Andreea, Andone, Sebastian Razvan, Balasa, Rodica Ioana |
| author_facet | Barcutean, Laura Iulia, Maier, Smaranda, Bajko, Zoltan, Motataianu, Anca, Romaniuc, Andreea, Andone, Sebastian Razvan, Balasa, Rodica Ioana, Barcutean, Laura Iulia, Maier, Smaranda, Bajko, Zoltan, Motataianu, Anca, Romaniuc, Andreea, Andone, Sebastian Razvan, Balasa, Rodica Ioana |
| author_sort | barcutean, laura iulia |
| container_issue | 1 |
| container_start_page | 12 |
| container_title | Acta Medica Marisiensis |
| container_volume | 65 |
| description | <jats:title>Abstract</jats:title> <jats:p> <jats:bold>Objective</jats:bold>: Interferon beta-1b (IFNβ-1b) was the first disease-modifying agent (DMT) used for the treatment of multiple sclerosis (MS). We aimed to evaluate the first patients with MS that started treatment in our clinic.</jats:p> <jats:p> <jats:bold>Methods</jats:bold>: An observational, retrospective study was performed on 78 patients that had continuous treatment with IFNβ-1b for more than 10 years. The collection of the demographical data and periodical clinical evaluation was performed on all patients. The disability was quantified using the Expanded Disability Status Scale (EDSS), creating two groups of patients, G1: EDSS < 4.0 and G2: EDSS ≥ 4.0. The hallmarks of the disability evolution were gathered by direct patient interview, such as the symptoms at onset and relapse frequency.</jats:p> <jats:p> <jats:bold>Results</jats:bold>: After more than 17 years of disease evolution, more than half (65.38%) of the patients present a mild disability score. The majority (54.90%) started treatment in the first three years after the onset, while the patients in G2 started treatment after more than 3 years from the onset. The initiation of IFNβ-1b lead to a significant reduction of the relapse rates. A reduced number of patients (<25%) transitioned from RRMS to SPMS.</jats:p> <jats:p> <jats:bold>Discussion</jats:bold>: Continuous evaluation of MS patients allows us to assess the possibility of prolonged treatment with IFNβ-1b and to differentiate the responders from non-responders. The clear reduction in relapse rates and disability progression, notably in patients that started treatment early ensure us into continuing administering this medication. Compared to historical cohorts, our lot had a slower disability evolution and a significant proportion hadn’t reach an important disability score.</jats:p> |
| doi_str_mv | 10.2478/amma-2019-0003 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjQ3OC9hbW1hLTIwMTktMDAwMw |
| imprint | Walter de Gruyter GmbH, 2019 |
| imprint_str_mv | Walter de Gruyter GmbH, 2019 |
| institution | DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1 |
| issn | 2247-6113 |
| issn_str_mv | 2247-6113 |
| language | English |
| last_indexed | 2024-03-01T13:25:10.514Z |
| match_str | barcutean2019interferonbeta1bforthetreatmentofmultiplesclerosismorethan10yearsofexperience |
| mega_collection | Walter de Gruyter GmbH (CrossRef) |
| physical | 12-18 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Walter de Gruyter GmbH |
| record_format | ai |
| recordtype | ai |
| series | Acta Medica Marisiensis |
| source_id | 49 |
| spelling | Barcutean, Laura Iulia Maier, Smaranda Bajko, Zoltan Motataianu, Anca Romaniuc, Andreea Andone, Sebastian Razvan Balasa, Rodica Ioana 2247-6113 Walter de Gruyter GmbH General Pharmacology, Toxicology and Pharmaceutics General Dentistry http://dx.doi.org/10.2478/amma-2019-0003 <jats:title>Abstract</jats:title> <jats:p> <jats:bold>Objective</jats:bold>: Interferon beta-1b (IFNβ-1b) was the first disease-modifying agent (DMT) used for the treatment of multiple sclerosis (MS). We aimed to evaluate the first patients with MS that started treatment in our clinic.</jats:p> <jats:p> <jats:bold>Methods</jats:bold>: An observational, retrospective study was performed on 78 patients that had continuous treatment with IFNβ-1b for more than 10 years. The collection of the demographical data and periodical clinical evaluation was performed on all patients. The disability was quantified using the Expanded Disability Status Scale (EDSS), creating two groups of patients, G1: EDSS < 4.0 and G2: EDSS ≥ 4.0. The hallmarks of the disability evolution were gathered by direct patient interview, such as the symptoms at onset and relapse frequency.</jats:p> <jats:p> <jats:bold>Results</jats:bold>: After more than 17 years of disease evolution, more than half (65.38%) of the patients present a mild disability score. The majority (54.90%) started treatment in the first three years after the onset, while the patients in G2 started treatment after more than 3 years from the onset. The initiation of IFNβ-1b lead to a significant reduction of the relapse rates. A reduced number of patients (<25%) transitioned from RRMS to SPMS.</jats:p> <jats:p> <jats:bold>Discussion</jats:bold>: Continuous evaluation of MS patients allows us to assess the possibility of prolonged treatment with IFNβ-1b and to differentiate the responders from non-responders. The clear reduction in relapse rates and disability progression, notably in patients that started treatment early ensure us into continuing administering this medication. Compared to historical cohorts, our lot had a slower disability evolution and a significant proportion hadn’t reach an important disability score.</jats:p> Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience Acta Medica Marisiensis |
| spellingShingle | Barcutean, Laura Iulia, Maier, Smaranda, Bajko, Zoltan, Motataianu, Anca, Romaniuc, Andreea, Andone, Sebastian Razvan, Balasa, Rodica Ioana, Acta Medica Marisiensis, Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience, General Pharmacology, Toxicology and Pharmaceutics, General Dentistry |
| title | Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_full | Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_fullStr | Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_full_unstemmed | Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_short | Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| title_sort | interferon beta-1b for the treatment of multiple sclerosis – more than 10 years of experience |
| title_unstemmed | Interferon Beta-1b for the Treatment of Multiple Sclerosis – More than 10 Years of Experience |
| topic | General Pharmacology, Toxicology and Pharmaceutics, General Dentistry |
| url | http://dx.doi.org/10.2478/amma-2019-0003 |